Skip to content

Blood Screening for Adult Colorectal Cancer

Evaluation of the Discriminatory Role of Blood TFPI-1 and TFPI-2 in Adult Colorectal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05577143
Acronym
BACCHUS
Enrollment
303
Registered
2022-10-13
Start date
2023-03-23
Completion date
2027-03-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Colorectal

Keywords

Oncology, Biology

Brief summary

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.

Interventions

None listed

Sponsors

University Hospital, Lille
Lead SponsorOTHER
Ministry of Health, France
CollaboratorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with suspected colorectal cancer for which colonoscopy is indicated. * Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated. Note. * If the post-inclusion colonoscopy is normal, no biopsy will be performed and patients will be assigned to the control group. * If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the "colorectal cancer" group or to the "polyps" group depending on the results of the anatomopathological analysis of the lesion(s)

Exclusion criteria

* All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis. * Endoscopic polypectomy without prior histological confirmation. * Emergency (occlusion or peritonitis) * Minor patients. * Persons of full age under legal protection or unable to express their consent * Persons not affiliated to a social security system or beneficiaries of such a system. * Pregnant women, women in labor or nursing mothers.

Design outcomes

Primary

MeasureTime frameDescription
Area under the ROC curve (AUC) of the TFPI-1 biomarkerAt 2 monthsthe AUC of the TFPI-1 biomarker to separate the 2 groups (CRC+ and control, i.e., asymptomatic population between 50 and 75 years with normal colonoscopy).

Secondary

MeasureTime frame
AUC of the TFPI-2 biomarker to separate the 2 groups (CRC+ and control).At 2 months
AUC of the discriminant score constructed by logistic regression with the 2 blood biomarkers as explanatory variables and the group type (CRC+ and control) as the variable to be explained.At 2 months
Extension of c-index to the 3-group case proposed by Van Calster B et al.At 2 months

Countries

France

Contacts

CONTACTPhilippe ZERBIB, MD,PhD
philippe.zerbib@chru-lille.fr0320445962
PRINCIPAL_INVESTIGATORPhilippe ZERBIB, MD,PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026